Utilizing liposomes and lipid nanoparticles to overcome challenges in breast cancer treatment

Q Medicine

Clinical Lipidology Pub Date : 2014-10-01 DOI:10.2217/clp.14.48

Reyhaneh Varshochian, Hosniyeh Hosseinzadeh, N. Gandomi, Faranak Tavassolian, F. Atyabi, R. Dinarvand

引用次数: 4

Abstract

Abstract Various lipid particulate drug delivery systems with liposomes as forefront have attracted increasing attention in cancer treatment, especially breast cancer therapy. Multidrug resistance and off-target cytotoxicity are among major obstacles faced by researchers in this area. To address these problems, various strategies, such as composition modifications, pegylation and attaching the targeting ligands, have been investigated. In this regard, a number of liposomal therapeutics could successfully reach the market and also several preclinical and clinical approaches are ongoing to upgrade lipid particles to multipotential carriers and potentiate their therapeutic efficacies. The current review is mainly concentrated on recent approaches in liposomal drug delivery systems intended for breast cancer therapy, and will have a glance at novel attributed studies based on other particulate lipid carriers.

查看原文本刊更多论文

利用脂质体和脂质纳米颗粒克服乳腺癌治疗中的挑战

以脂质体为前沿的各种脂质颗粒给药系统在癌症治疗特别是乳腺癌治疗中越来越受到关注。多药耐药和脱靶细胞毒性是该领域研究人员面临的主要障碍。为了解决这些问题，人们研究了各种策略，如组合物修饰、聚乙二醇化和靶向配体的连接。在这方面，许多脂质体疗法可以成功地进入市场，并且一些临床前和临床方法正在进行中，以将脂质颗粒升级为多潜能载体并增强其治疗效果。目前的综述主要集中在用于乳腺癌治疗的脂质体药物递送系统的最新方法，并将浏览基于其他颗粒脂质载体的新研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.